Cryolife Inc (NYSE:CRY) Director Sells $20,000.00 in Stock

Cryolife Inc (NYSE:CRY) Director C Elkins Ronald sold 1,000 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $20.00, for a total transaction of $20,000.00. Following the sale, the director now owns 99,849 shares in the company, valued at $1,996,980. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

C Elkins Ronald also recently made the following trade(s):

  • On Monday, November 6th, C Elkins Ronald sold 1,000 shares of Cryolife stock. The shares were sold at an average price of $19.03, for a total transaction of $19,030.00.

Cryolife Inc (NYSE CRY) opened at $18.65 on Friday. The company has a current ratio of 5.96, a quick ratio of 4.90 and a debt-to-equity ratio of 0.29. Cryolife Inc has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The stock has a market cap of $630.67, a P/E ratio of 66.61 and a beta of 0.82.

Cryolife (NYSE:CRY) last released its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.08. Cryolife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million during the quarter, compared to analyst estimates of $44.60 million. During the same quarter last year, the business earned $0.13 EPS. The company’s revenue was down 2.9% compared to the same quarter last year. sell-side analysts forecast that Cryolife Inc will post 0.28 earnings per share for the current year.

CRY has been the subject of a number of research reports. Lake Street Capital raised their price objective on shares of Cryolife to $26.00 and gave the company a “buy” rating in a report on Wednesday, October 11th. TheStreet lowered shares of Cryolife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Zacks Investment Research lowered shares of Cryolife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Northland Securities reiterated a “buy” rating and issued a $23.50 price objective on shares of Cryolife in a report on Monday, November 13th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $25.00 price objective on shares of Cryolife in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. Cryolife presently has an average rating of “Hold” and an average price target of $23.63.

Several hedge funds have recently made changes to their positions in CRY. Russell Investments Group Ltd. acquired a new stake in shares of Cryolife during the 3rd quarter worth approximately $6,164,000. William Blair Investment Management LLC acquired a new stake in shares of Cryolife during the 2nd quarter worth approximately $4,517,000. Macquarie Group Ltd. grew its position in shares of Cryolife by 16.0% during the 3rd quarter. Macquarie Group Ltd. now owns 1,609,284 shares of the medical equipment provider’s stock worth $36,531,000 after buying an additional 221,574 shares during the period. Thomson Horstmann & Bryant Inc. grew its position in shares of Cryolife by 139.0% during the 3rd quarter. Thomson Horstmann & Bryant Inc. now owns 224,518 shares of the medical equipment provider’s stock worth $5,096,000 after buying an additional 130,593 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Cryolife by 6.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,960,221 shares of the medical equipment provider’s stock worth $39,107,000 after buying an additional 110,973 shares during the period. 73.28% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thelincolnianonline.com/2018/01/14/insider-selling-cryolife-inc-cry-director-sells-20000-00-in-stock-updated-updated-updated.html.

About Cryolife

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply